Keytruda, Ibrance On Course To India Debut But What About Pricing?
This article was originally published in Scrip
Merck & Co's Keytruda (pembrolizumab), the first PD-1 inhibitor approved by the FDA last year, and Pfizer's breast cancer therapy, Ibrance (palbociclib), appear to be on course to a potential Indian debut after a key local expert panel recommended the products for marketing.
You may also be interested in...
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.